Trending Topics

Most patients with nAMD can achieve a 12-week aflibercept dosing interval

Approximately 68% of patients with neovascular age-related macular degeneration (nAMD) included in a retrospective, comparative study were able to achieve a 12-week (q12) aflibercept dosing interval within the first 2 years of treatment, while having a similar visual acuity outcome and fewer total injections to patients unable to achieve q12...